

Helping you meet the unique needs of **clinical development** and **commercialization of rare disease treatments**

Created **clinical development strategy to maximize market value** for a second-in-indication rare neurological disorder treatment, **resulting in >70% enrollment in SIX months**

350+

rare disease research projects conducted in the past five years



75+

rare disease indications worked on in the past five years

Issued **key takeaways on FDA draft guidance:**

Rare Diseases: Common Issues in Drug Development, Guidance for Industry →

50+

rare disease drugs supported in the past five years



Supported the validation and regulatory submission of multiple COAs used as **important efficacy endpoints in rare disease drug development programs** that have **achieved FDA and EMA labeling claims**

10+

countries where we have conducted rare disease projects



Actively involved in the **Rare Disease and Pediatric Center of Excellence**, a team of over 20 thought leaders across PPD focused on surfacing insights and innovation in the rare disease space

15+

peer-reviewed articles, research posters, and presentations published in rare diseases on average per year



Published two key and **highly-cited articles on hereditary angioedema**, a rare autosomal dominant disorder

1

The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression →

2

Economic costs associated with acute attacks and long-term management of hereditary angioedema →

Dedicated the entire spring 2019 issue of our publication, **The Evidence Forum**, to rare diseases →

Natural History Studies in Rare Diseases and Genetic Biomarkers →



Patient Engagement in Clinical Trial Protocol
Design and Recruitment Strategies: What Does It Mean for Orphan Drug Manufacturers? →

Clinical Outcome Assessment Selection for Rare Disease Trial Programs →



How **Social Media** Can Be Used to **Understand What Matters** to People with Rare Diseases →

TOPICS INCLUDED